Latest Conference Articles

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

Interim phase 2 data suggest bimiralisib could help patients with actinic keratosis achieve complete or partial clearance of lesions in as little as 2 weeks.

Combined analysis of data from a pair of post-registrational studies demonstrate the clinical profile and patient opinion on treatment with tirbanulin.

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

In this interview at AAD 2025, Silverberg discusses important facts for dermatologists to know in the management of molluscum contagiosum.

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

In this interview, Aguh answers several key questions about the efforts of the Skin of Color Society and improving diversity in clinical research.

HCPLive spoke with Golden at AAAAI on the pitfalls of diagnosing all patients with insect stings for insect sting allergies.

Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

Findings were presented from the AROMA registry study in 3 abstracts at the AAAAI,WAO Joint Congress.

Casale discussed data from the phase 1b/2a BEACON study he presented at the AAAAI/WAO Joint Congress.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

This quiz, the second in a series of 4, tests your knowledge on cryosurgery and PDT recommendations for actinic keratosis based on the 2021 AAD guidelines.

HCPLive spoke with Lam at AAAAI about how allergists should establish endoscopic sinus surgery expectations with patients regarding risks and benefits ahead of the operation.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

Pongdee discussed research presented at the AAAAI/WAO Joint Congress that focused on improving diagnosis of indolent systemic mastocytosis.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.

Phase 2 data from AAAAI 2025 shows peanut oral immunotherapy boosts desensitization in children with high-threshold peanut allergy, enabling safe meal-size peanut consumption.

Castells describes what’s missing from the current treatment landscape and the potential implications of elenestinib for indolent systemic mastocytosis.

John Barbieri, MD, MBA, discusses recent data examining factors associated with formation of benzene in OTC benzoyl peroxide products.

This quiz, the first in a series of 4, tests your knowledge on prevention and treatment of actinic keratosis based on the 2021 AAD guidelines.

Subgroup analyses of the real-world REALITI-A study were presented at the 2025 AAAAI/WAO Joint Congress.

Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.

A Johns Hopkins study presented at AAAAI 2025 found omalizumab was more effective than oral immunotherapy for food allergies, with fewer dropouts due to adverse events.

Metz shared highlights from 2 presentations he gave on barzolvolimab’s efficacy at the AAAAI/WAO Joint Congress.